Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Scagliotti, G.V.
Right arrow Articles by Selvaggi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scagliotti, G.V.
Right arrow Articles by Selvaggi, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:S83-S86, 1999
© 1999 European Society for Medical Oncology

Reviews

Multidrug resistance in non-small-cell lung cancer

G.V. Scagliotti, S. Novello and G. Selvaggi

University of Turin, Department of Clinical & Biological Sciences, Azienda Ospedaliera S. Luigi – Orbassano (Torino) Italy

Correspondence to: Prof. G.V. Scagliotti, Università di Torino, Dipartimento di Scienze Cliniche & Biologiche, Azienda Ospedaliera S. Luigi, Regione Gonzole, 10, 10043 Orbassano (Torino), Italy, E-mail: scagliotti{at}ihnet.it

Resistance to cytotoxic drugs is an important cause of treatment failure. The causes are complex and may be determined by a combination of the tumour characteristics, such as the proportion of resting cells, adequacy of blood supply, and specific cellular mechanisms, as in the multidrug resistance phenotype. In lung cancer four types of multidrug resistance have been defined on the basis of the cellular drug targets involved, i.e., classical multidrug resistance (MDR), non-P-glycoprotein MDR (also called MRP), atypical MDR (mediated through altered expression of topoisomerases II) and lung resistance-related protein. In lung cancer the role of the different forms of multidrug resistance is complex and only partially understood.

lung resistance-related protein, multidrug resistance, multidrug resistance protein, non-small-cell lung cancer, P-glycoprotein, topoisomerases


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.